Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 20,548
Companies: 1,769
Drugs tracked: 4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

Double-Blind, Randomized, Placebo-Controlled, Phase 1b, Pharmacodynamic Trial of TEV-56192 Following a Single Intravenous Administration in Healthy Participants

Drugs administration

Exploratory study to assess the pharmacokinetic interaction of doxepin with adrenaline after a concomitant co-administration using the Anapen® device and to compare the adrenaline comparative bioavailability with Anapen®500 commercial form in healthy normal weight male subjects

First-In-Human study evaluating the Safety of administration of ABD-3001 to Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes

GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).

JWK007 Single intravenous infusion administration

Nicotine Pouches

Olutasidenib Investigational Agent Administration

Open label, Phase I study to assess and compare the pharmacokinetic parameters after multiple oral administration of stiripentol 1000 mg in renal impaired patients and matching controls with normal renal function

Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects.

Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation at 4 different strengths versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects

PET study of changes in [11C]AZ14132516 uptake following administration of multiple AZD7798 doses to patients with Crohn’s disease.

PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION

Pharmacy-based methadone administration and dispensing

Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

RANDOMISED, CROSSOVER, SIMPLE-BLINDED, BIOEQUIVALENCE CLINICAL TRIAL OF ALMOTRIPTAN 12.5 MG ORODISPERSIBLE TABLETS VERSUS ALMOTRIPTAN 12.5 MG FILM-COATED TABLETS, AFTER A SINGLE ORAL DOSE ADMINISTRATION TO HEALTHY VOLUNTEERS UNDER FASTING

Randomised, bioequivalence clinical trial of atorvastatin 80 mg capsules vs atorvastatin 80 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions in crossover replicated design.

Randomised, bioequivalence clinical trial of rasagiline 1 mg capsules vs rasagiline 1 mg tablets, after a single oral dose administration to healthy volunteers under fasting conditions in crossover replicated design.

Randomised, crossover bioequivalence clinical trial of donepezil 5 mg capsules vs donepezil 5 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions

Randomised, crossover bioequivalence clinical trial of edoxaban 60 mg tablets versus edoxaban 60 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

Randomised, crossover bioequivalence clinical trial of escitalopram 10 mg capsules versus escitalopram 10 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

Randomised, crossover bioequivalence clinical trial of linagliptin/metformin 2.5 mg/1000 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fed conditions.

Frequently asked questions